Open Access Open Access  Restricted Access Subscription or Fee Access

A Review Article on Obesity: Classification, Biomarkers, Prevention and Treatment

Hitesh Kumar


Obesity is a complicated condition characterised by an excess of body fat. According to the World Health Organization (WHO) and the National Institutes of Health, a person is overweight if their BMI is between 25.0 and 29.91 kg / m2, and obese if their BMI is greater than 30.0 kg / m2. Drugs such as psychiatric pharmaceuticals, diabetic therapies, antihypertensives, contraceptives, steroid hormones, antihistamines, and protease inhibitors, are linked to weight gain. Due to the fact that 50 per cent or more of the fat mass is subcutaneous, skinfold thickness has long been used to assess fat as well as its distribution. CT scans, fat cell size and numbers, ultrasound, bioelectrical impedance and MRI scans are some of the other modalities used for the evaluation. It can be said that a person gains weight when energy input exceeds energy output. Biomarkers are biological markers that indicate the presence of various diseases in our bodies. Biomarkers such as c-peptide, oxidative stress, insulin and proinsulin, adiponectin, microRNAs are also reviewed. Intragastric balloon and bariatric surgery can be performed as an alternative method of treatment.


Obesity, comorbidities, biomarkers.

Full Text:



Nimptsch K, Konigorski S, Pischon T. Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. Metabolism. 2019 Mar 1;92:61-70.

Endalifer ML, Diress G. Epidemiology, predisposing factors, biomarkers, and prevention mechanism of obesity: a systematic review. Journal of obesity. 2020 Oct;2020.

Suvan JE, Finer N, D'Aiuto F. Periodontal complications with obesity. Periodontology 2000. 2018 Oct;78(1):98-128.

Hill JO, Peters JC. Biomarkers and functional foods for obesity and diabetes. British Journal of Nutrition. 2002 Nov;88(S2):S213-8.

Sroka-Oleksiak A, Młodzińska A, Bulanda M, Salamon D, Major P, Stanek M, Gosiewski T. Metagenomic analysis of duodenal microbiota reveals a potential biomarker of dysbiosis in the course of obesity and type 2 diabetes: a pilot study. Journal of Clinical Medicine. 2020 Jan 29;9(2):369.

Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention: the case for action. International journal of obesity. 2002 Mar;26(3):425-36.

Swinburn B, Gill T, Kumanyika S. Obesity prevention: a proposed framework for translating evidence into action. Obesity reviews. 2005 Feb;6(1):23-33.

Wadden TA, Osei S. The treatment of obesity: an overview.

Campfield LA, Smith FJ, Burn P. Strategies and potential molecular targets for obesity treatment. Science. 1998 May 29;280(5368):1383-7.


  • There are currently no refbacks.

Copyright (c) 2023 Research & Reviews: A Journal of Drug Design & Discovery